These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17616675)

  • 1. Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin.
    Sizemore S; Cicek M; Sizemore N; Ng KP; Casey G
    Cancer Res; 2007 Jul; 67(13):6183-91. PubMed ID: 17616675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kalopanaxsaponin A inhibits PMA-induced invasion by reducing matrix metalloproteinase-9 via PI3K/Akt- and PKCdelta-mediated signaling in MCF-7 human breast cancer cells.
    Park SK; Hwang YS; Park KK; Park HJ; Seo JY; Chung WY
    Carcinogenesis; 2009 Jul; 30(7):1225-33. PubMed ID: 19420016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ezrin silencing by small hairpin RNA reverses metastatic behaviors of human breast cancer cells.
    Li Q; Wu M; Wang H; Xu G; Zhu T; Zhang Y; Liu P; Song A; Gang C; Han Z; Zhou J; Meng L; Lu Y; Wang S; Ma D
    Cancer Lett; 2008 Mar; 261(1):55-63. PubMed ID: 18155831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1.
    Ramer R; Hinz B
    J Natl Cancer Inst; 2008 Jan; 100(1):59-69. PubMed ID: 18159069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of the influence of Ehm2 on the aggressiveness of breast cancer cells through regulation of matrix metalloproteinase-9 expression.
    Yu H; Ye L; Mansel RE; Zhang Y; Jiang WG
    Mol Cancer Res; 2010 Nov; 8(11):1501-12. PubMed ID: 21047774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological significance of podocalyxin and phosphorylated ezrin in uterine endometrioid adenocarcinoma.
    Yasuoka H; Tsujimoto M; Inagaki M; Kodama R; Tsuji H; Iwahashi Y; Mabuchi Y; Ino K; Sanke T; Nakamura Y
    J Clin Pathol; 2012 May; 65(5):399-402. PubMed ID: 22412054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression.
    Nikolova V; Koo CY; Ibrahim SA; Wang Z; Spillmann D; Dreier R; Kelsch R; Fischgräbe J; Smollich M; Rossi LH; Sibrowski W; Wülfing P; Kiesel L; Yip GW; Götte M
    Carcinogenesis; 2009 Mar; 30(3):397-407. PubMed ID: 19126645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution and expression of CD44 isoforms and Ezrin during prostate cancer-endothelium interaction.
    Harrison GM; Davies G; Martin TA; Jiang WG; Mason MD
    Int J Oncol; 2002 Nov; 21(5):935-40. PubMed ID: 12370738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal ezrin localization is associated with clinicopathological features in invasive breast carcinomas.
    Sarrió D; Rodríguez-Pinilla SM; Dotor A; Calero F; Hardisson D; Palacios J
    Breast Cancer Res Treat; 2006 Jul; 98(1):71-9. PubMed ID: 16538541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of Ezrin in gastric carcinoma and its significance].
    Shi RL; Li JF; Qu Y; Chen XH; Gu QL; Zhu ZG; Liu BY
    Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Sep; 9(5):433-5. PubMed ID: 17043968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype.
    Kumar B; Koul S; Khandrika L; Meacham RB; Koul HK
    Cancer Res; 2008 Mar; 68(6):1777-85. PubMed ID: 18339858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RhoB enhances migration and MMP1 expression of prostate cancer DU145.
    Yoneda M; Hirokawa YS; Ohashi A; Uchida K; Kami D; Watanabe M; Yokoi T; Shiraishi T; Wakusawa S
    Exp Mol Pathol; 2010 Feb; 88(1):90-5. PubMed ID: 19782069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor and invasion in prostate cancer.
    Hara T; Miyazaki H; Lee A; Tran CP; Reiter RE
    Cancer Res; 2008 Feb; 68(4):1128-35. PubMed ID: 18281488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Podocyte cytoskeleton is connected to the integral membrane protein podocalyxin through Na+/H+-exchanger regulatory factor 2 and ezrin.
    Takeda T
    Clin Exp Nephrol; 2003 Dec; 7(4):260-9. PubMed ID: 14712354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium hydrogen exchanger and phospholipase D are required for alpha1-adrenergic receptor stimulation of metalloproteinase-9 and cellular invasion in CCL39 fibroblasts.
    Taves J; Rastedt D; Canine J; Mork D; Wallert MA; Provost JJ
    Arch Biochem Biophys; 2008 Sep; 477(1):60-6. PubMed ID: 18539131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinase-1 is a crucial bone metastasis factor in a human breast cancer-derived highly invasive cell line.
    Okuyama N; Matsumine A; Kosugi R; Wakabayashi H; Uchida A
    Oncol Rep; 2008 Dec; 20(6):1497-504. PubMed ID: 19020733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Penta-O-galloyl-beta-D-glucose suppresses prostate cancer bone metastasis by transcriptionally repressing EGF-induced MMP-9 expression.
    Kuo PT; Lin TP; Liu LC; Huang CH; Lin JK; Kao JY; Way TD
    J Agric Food Chem; 2009 Apr; 57(8):3331-9. PubMed ID: 19320436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yanhusuo extract inhibits metastasis of breast cancer cells by modulating mitogen-activated protein kinase signaling pathways.
    Gao JL; Shi JM; He K; Zhang QW; Li SP; Lee SM; Wang YT
    Oncol Rep; 2008 Oct; 20(4):819-24. PubMed ID: 18813823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of PMA-induced tumor cell invasion by capillarisin via the inhibition of NF-kappaB-dependent MMP-9 expression.
    Lee SO; Jeong YJ; Kim M; Kim CH; Lee IS
    Biochem Biophys Res Commun; 2008 Feb; 366(4):1019-24. PubMed ID: 18088599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of exogenous tissue factor on estrogen receptor alpha expression in breast cancer cells: involvement of beta1-integrin, PAR2, and mitogen-activated protein kinase activation.
    Collier ME; Li C; Ettelaie C
    Mol Cancer Res; 2008 Dec; 6(12):1807-18. PubMed ID: 19074826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.